Funding opportunities
Open and upcoming programs from Canadian funders and US federal grants (Grants.gov). Deadlines first, then rolling intakes.
Expanded Surveillance for Pediatric Infectious Diseases
Centers for Disease Control and Prevention - ERA · Deadline not published
The purpose of this Notice of Funding Opportunity (NOFO) is to support a network of U.S. institutions that will conduct standardized, prospective, active surveillance of pediatric acute respiratory illness (ARI) and acute gastroenteritis (AGE). The network will focus on respiratory and enteric viruses among pediatric patients seeking healthcare. In addition, the network will generate robust estimates of the effectiveness of influenza, rotavirus, respiratory syncytial virus (RSV) and other prevention products against respiratory and enteric viral illnesses in this population. Recipients will identify AGE and ARI illnesses among patients seeking healthcare or diagnostic testing for acute illness among inpatient and emergency department populations. Recipients may also include patients seeking care in outpatient clinics, such as urgent care centers, as an optional activity. This is a multi-component NOFO. You must apply for ComponentA (Core Component). You may also apply for one or more optional components. Component A – Core Component (Required) Support inpatient and emergency department pediatric surveillance Follow the standardized protocol established by CDC Optional Components Co Awards range from $850,000 to $1,140,000.
Improving Protection against Influenza and Other Respiratory Pathogens: the US Flu VE Network
Centers for Disease Control and Prevention - ERA · Deadline not published
The purpose of this notice of funding opportunity (NOFO) is to continue the work of the US Influenza Vaccine Effectiveness (Flu VE) Network. Influenza and other respiratory pathogens are important causes of morbidity, mortality, and healthcare burden across the age spectrum. This network provides evidence needed to improve the effectiveness of influenza and other respiratory pathogen vaccines. You would propose work under this NOFO to include: 1) annual VE and correlates of protection surveillance from active enrollment and systematic respiratory pathogen testing of outpatients; 2) electronic acute respiratory illness and VE surveillance; 3) household transmission research studies; and 4) immunogenicity research studies. This is a multi-component NOFO of Component A, B, C and D. The anticipated award number for each component is: five for Component A (VE and correlates of protection), one for Component B (Coordination and surge capacity), two for Component C (Household transmission studies) and three for Component D (Immunogenicity studies). You are required to apply for either Component A (VE and correlates of protection) or B (Coordination and surge capacity) but not both. If you Awards range from $1,350,000 to $3,550,000.
SEFSC Bluefin Tuna Research Program
DOC NOAA - ERA Production · Deadline 2026-12-31
The objective of the program is to provide a basis for advancing science-based fisheries management for Atlantic bluefin tuna. Such advancement will depend upon improvements in understanding of the fisheries, total abundance, and biology of bluefin tuna, especially regarding the effects of mixing and movement between the eastern and western Atlantic populations. Contracting Parties to the International Commission for the Conservation of Atlantic Tunas (ICCAT), of which the US is one, and other partners have embarked upon a multi-year research program on bluefin tuna as a step toward improving ICCAT's science-based management of Bluefin fisheries. Research sponsored under this funding opportunity represents a contribution to this partnership. Proposals that demonstrate collaborations with the ICCAT Atlantic Bluefin Tuna Research Program and other ICCAT partners are strongly encouraged. Awards range from $25,000 to $300,000.
Solid Waste Management Grant Program
Rural Utilities Service · Deadline 2026-12-31
Funds may be used to: (a) Provide technical assistance and/or training to reduce the solid waste stream through reduction, recycling, and reuse. (b) Provide training to enhance operator skills in maintaining and operating active landfills. (c) Provide technical assistance and/or training for operators of landfills which are closed or will be closed in the near future with the development/implementation of closure plans, future land use plans, safety and maintenance planning, and closure scheduling within permit requirements. (d) Evaluate current landfill conditions to determine the threats to water resources. (e) Pay the expenses associated with providing the technical assistance and/or training authorized in paragraphs (a) through (d) of this section. Grant funds may not be used to: (a) Duplicate current services or replace or substitute support normally provided by other means, such as those performed by an association's consultant in developing a project, including feasibility, design, and cost estimates. (b) Fund political or lobbying activities. (c) Purchase real estate or vehicles, improve or renovate office space, or repair and maintain privately owned property. (d) Pay the Awards up to $1,000,000.
Technical Assistance and Training Grant Program
Rural Utilities Service · Deadline 2026-12-31
Funds may be used to pay expenses associated with providing technical assistance and/or training (TAT) to: Identify and evaluate solutions to water problems relating to source, storage, treatment, or distribution; identify and evaluate solutions to waste problems relating to collection, treatment, or disposal: assist applicants, that have filed a pre-application with RUS, in the preparation of water and/or waste loan and/or grant applications; and/or provide technical assistance and/or training to water/wastewater system personnel that will improve the management, operation and maintenance of water and waste disposal facilities. Grant funds may not be used to duplicate current services, such as those performed by an association’s consultant in developing a project; fund political or lobbying activities; pay for capital assets; purchase real estate or vehicles; improve or renovate office space, or repair and maintain privately owned property; pay the costs for construction, improvement, rehabilitation, modification or operation and maintenance of water, wastewater, and solid waste disposal facilities; and pay costs incurred prior to effective date of grant.
ERDC Broad Agency Announcement
Engineer Research and Development Center · Deadline 2027-01-01
The U.S. Army Corps of Engineers (USACE) Engineer Research and Development Center (ERDC) is issuing this announcement for various research and development topic areas. The ERDC consists of the Coastal and Hydraulics Laboratory (CHL), the Geotechnical and Structures Laboratory (GSL), the Environmental Laboratory (EL) and the Information Technology Laboratory (ITL) in Vicksburg, Mississippi, the Cold Regions Research and Engineering Laboratory (CRREL) in Hanover, New Hampshire, the Construction Engineering Research Laboratory (CERL) in Champaign, Illinois, and the Geospatial Research Laboratory (GRL) in Alexandria, Virginia. The ERDC is responsible for conducting research in the broad fields of hydraulics, dredging, coastal engineering, instrumentation, oceanography, remote sensing, geotechnical engineering, earthquake engineering, soil effects, vehicle mobility, self-contained munitions, military engineering, geophysics, pavements, protective structures, aquatic plants, water quality, dredged material, treatment of hazardous waste, wetlands, physical/mechanical/ chemical properties of snow and other frozen precipitation, infrastructure and environmental issues for installations, com Awards up to $999,999,999.
Centers of Excellence in Healthcare Quality and Safety
Centers for Disease Control - NCEZID · Deadline not published
This Program will create a collaborative network of healthcare systems, facilities and public health partners to rapidly detect, respond to, and prevent threats to patient and healthcare worker safety. This Program will support work that improves the safety, quality and resilience of U.S. healthcare delivery. The Program will be made up of healthcare systems inclusive of multiple facilities in a variety of settings, including acute care hospitals (particularly community hospitals, critical access, hospitals, and rural hospitals), long-term acute care hospitals, nursing homes, dialysis centers, emergency rooms and urgent care centers, outpatient facilities and home health providers. The Program will include healthcare systems and facilities partnering with public health departments and other entities or groups with relevant expertise. However, each individual applicant is not expected to have all elements. Awards range from $3,500,000 to $22,000,000.
National Parks Business Plan Internship
National Park Service · Deadline 2027-01-04
The National Parks Business Plan Internship (BPI) goal is to jointly administer a graduate-level internship program focused on improving the business management and operational health of our national parks and NPS programs. The internship program should: Provide students with in-depth training on NPS business management and operations, exposure to park and/or program level operations, and the opportunity to conduct substantive analysis and evaluation which lead to recommendations that improve strategic planning and management decision-making. Encourage highly qualified graduate students from professional disciplines underrepresented in the NPS workforce (Master of Business Administration, Master of Public Policy, Master of Environmental Management, and similar degree programs) to explore federal careers with conservation and land management agencies. Cultivate a lifelong stewardship ethic for public lands in graduate students from top universities. Eligible recipients are State, local and tribal governments, other public entities, educational institutions, and private nonprofit organizations. Awards up to $1,700,000.
Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
National Institutes of Health · Deadline not published
The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), including the participating Institutes, Centers and Offices, intend to publish a Notice of Funding Opportunity (NOFO) to invite eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, and Fast-Track (NIH only) grant applications for the Small Business Transition Grant. Through this NOFO, NIH and CDC will support early-career scientists as they transition into entrepreneurship. In addition to funding research and development efforts at the SBC, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects, including identification of complementary industry mentors and career development resources. This NOFO will utilize the R43/R44 activity code. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH and CDC awarding components identified in this NOFO
Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
National Institutes of Health · Deadline not published
The National Institutes of Health (NIH), including the participating Institutes, Centers and Offices, intends to publish a Notice of Funding Opportunity (NOFO) to invite eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, and Fast-Track grant applications for the Small Business Transition Grant. Through this NOFO, NIH will support early-career scientists transitioning to entrepreneurship. In addition to funding research and development efforts at the SBC, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects, including identification of complementary industry mentors and career development resources. This NOFO will utilize the R41/R42 activity code. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this NOFO are encouraged to begin to consider applying for this new NOFO. This opportunity is av
Mechanistic Toxicology of METALS: Metal Exposure, Transport, Action, Localization, and Susceptibility (RP1 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
The purpose of this funding opportunity is to support mechanistic research to understand how exposure to metals and metal-containing compounds alters biological processes relevant to human health. Of particular interest are studies that elucidate the absorption, distribution, transport, cellular trafficking, biological interactions, and mechanisms of action of metals, including mechanisms through which metals may alter immune homeostasis, cross the placental barrier, or gain access to and affect the central nervous system. Studies may employ experimental models, new approach methodologies, computational approaches, or leverage human biospecimens where these approaches are used to address defined mechanistic hypotheses. Awards range from $100,000 to $500,000.
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
National Institutes of Health · Deadline 2027-01-07
The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole.This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For the purpose of this NOFO, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low ris Awards up to $375,000.
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
National Institutes of Health · Deadline 2027-01-07
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within.
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-01-07
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. Awards up to $500,000.
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-01-07
This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control.
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Institutes of Health · Deadline 2027-01-07
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health · Deadline 2027-01-07
Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. Awards up to $499,999.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-01-07
The goal of this NOFO is to support R21 applications for novel theory and methods development that better delineate how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary across the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, simulations, and validation using available large-scale datasets
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-01-07
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-01-07
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.